Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV

Real world data in a black population

Jaspreet Banga, MD, MPH, Sobia Nizami, MD, Jihad Slim, MD, Sandhya Nagarakanti, MD, Mario Portilla, RN, Shobha Swaminathan, MD

Abstract

Treatment of hepatitis C virus (HCV) infection for patients with human immunodeficiency virus (HIV) has improved with direct acting antivirals. However, outcomes among Black persons treated with ledipasvir/sofosbuvir (LDV/SOF) may be inferior to non-Blacks. We assessed responses to LDV/SOF in a cohort of Black HIV/HCV coinfected persons.

Retrospective chart reviews were conducted for Black, genotype 1 (GT1), HIV/HCV coinfected patients treated with LDV/SOF at 3 hospitals in Newark, NJ between January 2014 and July 2016. Data collected included demographics, HIV treatment history, HCV treatment duration, and response.

One hundred seventeen HIV/HCV coinfected Black patients started treatment with LDV/SOF but 5 had no follow-up data and 5 prematurely discontinued treatment (1 due to side effects). We included 107 HIV/HCV coinfected patients who completed LDV/SOF at all 3 sites. The study population was 65% male, median age 58 years, 26% had cirrhosis, and 78% had GT1a. Thirty-one percent were treatment experienced but none with prior NS5a treatment. At baseline, median CD4 count was 680 cells/mm², HIV viral load (VL) was <40 copies/mL in 94% and median HCV VL was 2,257,403 IU/mL. Twenty-nine percent of patients changed antiretroviral treatment before LDV/SOF treatment due to drug interactions. Six, 89, and 12 patients completed 8, 12, and 24 weeks of LDV/SOF, respectively. Overall sustained virologic response rate was 93% with 7 relapses.

In this real-world cohort of Black, GT1, HIV/HCV coinfected patients, LDV/SOF had high sustained virologic response 12 weeks post completion of treatment rate of 93%. This data supports the overall high efficacy of LDV/SOF in a historically difficult-to-treat patient population.

Abbreviations: 3TC = lamivudine, ABC = abacavir, ART = antiretroviral treatment, ATV/r = ritonavir-boosted atazanavir, DAAAs = direct acting antivirals, DTG = dolutegravir, EFV = efavirenz, FTC = emtricitabine, GT1 = genotype 1, HCV = hepatitis C virus, HCV VL = hepatitis C virus viral load, HIV = human immunodeficiency virus, HIV VL = human immunodeficiency virus viral load, INSTI = integrase strand transfer inhibitor, LDV/SOF = ledipasvir/sofosbuvir, PI = protease inhibitor, PPI = proton pump inhibitor, RAL = raltegravir, RPV = ritpirvirine, SVR = sustained virologic response, SVR12 = sustained virologic response 12 weeks post completion of treatment, TDF = tenofovir disoproxil fumarate, VL = viral load.

Keywords: coinfection, hepatitis C virus, HIV/HCV coinfection, ledipasvir/sofosbuvir

1. Introduction

Hepatitis C virus infection (HCV) is a significant cause of morbidity and mortality globally. In the United States, an estimated 1% of the population lives with the disease.[1] About 1/4 of patients with human immunodeficiency virus (HIV) are coinfected with HCV.[2] Patients coinfected with HIV/HCV have more rapid progression to liver failure and hepatocellular carcinoma, compared to HCV mono-infected patients.[3] Persons with HCV/HIV coinfection also have higher rates of mortality and morbidity related to HCV infection than HCV mono-infected persons.[4] This increased risk persists despite effective treatment of HIV infection.[5-8] The goal of HCV treatment is to achieve and maintain undetectable levels of HCV RNA 12 weeks after completion of therapy, known as sustained virologic response (SVR). Response rates to treatment of HCV infection with pegylated interferon and ribavirin have been poor among those with HIV coinfection.[4] The advent of direct acting antivirals (DAAs) for HCV infection has improved response rates significantly. One such DAA regimen is ledipasvir/sofosbuvir (LDV/SOF); ledipasvir is a HCV nonstructural protein 5A (NS5a) inhibitor with antiviral activity against HCV genotypes 1a and 1b.
and sofosbuvir is a nucleotide polymerase inhibitor approved for treatment of HCV genotypes 1 to 4. The combination LDV/SOF is approved for treatment of HCV genotype 1, 4, 5, and 6. Several randomized controlled trials have demonstrated the efficacy of LDV/SOF in achieving SVR in patients with chronic HCV infection, regardless of prior HCV treatment, length of treatment course, or HIV coinfection. However, data regarding efficacy of LDV/SOF among different racial groups remains unclear. Some studies have demonstrated significantly lower SVR rates amongst Black HIV/HCV coinfected patients; this racial difference in treatment response was not seen in the mono-infected analyses.14-16 In this study, we conducted a retrospective chart review to assess real-world responses to LDV/SOF in a cohort of Black HIV/HCV coinfected persons in Newark, NJ.

2. Methods

Retrospective chart reviews were conducted at 3 hospitals in Newark, NJ between January 2014 and July 2016. Inclusion criteria for the study were: patients > 18 years old who had HIV infection; HCV genotype 1 (GT1) infection; been treated with LDV/SOF; no prior treatment with any NS5a or nonstructural protein 3b inhibitors; and self-identified as Black. Patients with no prior HCV treatment as well as those with prior treatment failure with pegylated interferon only with or without ribavirin were included. At each of the 3 sites, subject records were accessed via the electronic medical record. The study was approved by the institutional review board at each participating site. Data collected included demographics, HCV treatment history, duration of LDV/SOF regimen, treatment response, CD4 count and HIV viral load (VL), antiretroviral treatment (ART), use of proton pump inhibitors (PPI), and adverse events. Descriptive and summary statistics were used to analyze population and SVR rates. Primary efficacy end point was the rate of SVR, defined as absence of quantifiable HCV RNA in serum 12 weeks after the end of therapy. Relapse was defined as obtaining an undetectable HCV VL that became detectable with the same genotype subtype on laboratory data either 4 weeks or 12 weeks post completion of treatment.

3. Results

A total of 117 HIV/HCV coinfected Black patients initiated treatment with LDV/SOF during the study period. Of these patients, 107 completed treatment and follow-up at all 3 sites (Table 1). Five patients did not have follow-up data and 5 patients prematurely discontinued therapy, 1 due to side effects (0.9%). The study population was 65% male, median age 58 years, 26% had cirrhosis, and 78% had GT1a. Thirty-one percent of patients were treatment experienced but none with prior NS5a treatment. At baseline, median CD4 count was 680 cells/mm³, HIV VL was <40 copies/mL in 94% and median HCV VL was 2,257,403 IU/mL.

Patients were continued on HIV treatment during HCV therapy. Twenty-nine percent of patients (31/107) changed ART before LDV/SOF treatment due to anticipated drug-drug interactions with LDV/SOF. Notably, 14/28 (50%) of patients on a protease inhibitor at baseline were switched to integrate strand transfer inhibitor (INSTI) based regimens before starting treatment with LDV/SOF. Of the 12 people on efavirenz at baseline, 7 were switched off efavirenz before LDV/SOF treatment. Majorit of the patients were on INSTI based regimens (63/107, or 61%) at week 0 of LDV/SOF treatment. Four of the 31 patients who changed ART regimen before LDV/SOF switched back to their original regimen after completion of HCV treatment. Six, 89, and 12 patients completed 8, 12, and 24 weeks of LDV/SOF, respectively. Duration of the treatment was at the discretion of the treating physician. Of the 6 patients who received 8 weeks of treatment, none were cirrhotic and the median HCV VL at baseline was 1,186,466 copies/mL. Overall SVR rate was 93% (Table 2) with 7 relapses (Table 3).

Treatment was well tolerated, with 19/107 (18%) of patients reporting any new symptoms, most commonly fatigue and headaches. No adverse events reported were thought to be related to LDV/SOF. Seven percent of patients received PPI treatment while on LDV/SOF; all patients receiving PPI during LDV/SOF treatment achieved SVR. Five patients (5%) had HIV VL breakthrough (>200 copies/mL); 3/5 achieved SVR.

4. Discussion

Despite similar rates of SVR demonstrated in clinical trials for HCV mono-infected and HIV/HCV coinfected patients, Black patients had significantly lower response rates than other patients. Black HIV/HCV coinfected patients have been historically considered a difficult-to-treat population secondary to more comorbidities, higher drug–drug interactions, and higher prevalence of ongoing barriers to care (such as neuropsychiatric disease, unstable housing, lower socioeconomic status, active drug/alcohol use).114 In this retrospective review of 107 Black HIV/HCV coinfected patients who completed treatment with ledipasvir-sofosbuvir, the overall SVR rate was 93%. This rate is comparable to the overall rates of SVR demonstrated in clinical trials and supports real-world high efficacy of LDV/SOF in Black HIV/HCV coinfected patients.

Table 1
Demographic characteristics of patients at baseline (N = 107).

| Characteristic                        | Value |
|--------------------------------------|-------|
| Median age (yrs)                     | 58    |
| Male sex, N (%)                      | 69 (65) |
| HCV 1a genotype, N (%)               | 83 (78) |
| Median HCV viral load (IU/mL)        | 2,257,403 |
| Prior interferon treatment, N (%)    | 33 (31) |
| Cirrhosis, N (%)                     | 28 (26) |
| Median CD4 cell count (cells/μL)     | 680   |

HCV = hepatitis C virus.

Table 2
Sustained virologic outcomes.

|          | SVR12 rates | Relapse |
|----------|-------------|---------|
| Overall  | 93%         | 7/107   |
| By duration |
| 8 weeks  | 67%         | 2/6     |
| 12 weeks | 96%         | 4/89    |
| 24 weeks | 92%         | 1/12    |
| By ART class |
| INSTI    | 90%         | 3/65    |
| PI       | 93%         | 1/14    |
| Included efavirenz | 80%   | 1/5     |
| Other    | 91%         | 2/23    |
| Cirrhotics | 96%       | 1/28    |

ART = antiretroviral treatment, INSTI = integrase inhibitor strand transfer inhibitor, PI = protease inhibitor, SVR12 = sustained virologic response 12 weeks post completion of treatment.
Table 3
Characteristics of patients who relapsed.

| Patient | Age | Cirrhosis | Baseline HCV VL (IU/mL) | ART on LDV/SOF | Genotype | Prior tx | Duration (weeks) | HIV VL breakthrough during tx |
|---------|-----|-----------|------------------------|-----------------|----------|---------|----------------|-----------------------------|
| 1       | 57  | No        | 5,000,000              | DTG/ABC/3TC      | 1a       | Yes     | 12             | No                          |
| 2       | 59  | Yes       | 1,740,200              | RPV/TDF/FTC      | 1a       | Yes     | 24             | No                          |
| 3       | 68  | No        | 9,659,736              | RPV/TDF/FTC      | 1a       | Yes     | 12             | No                          |
| 4       | 54  | No        | 9,506,970              | EFV/TDF/FTC      | 1a       | No      | 12             | Yes                         |
| 5       | 56  | No        | 2,205,076              | ATV/r/TDF/FTC    | 1a       | No      | 8              | No                          |
| 6       | 61  | No        | 12,815,000             | ATV/r/TDF/FTC    | 1a       | No      | 8              | No                          |
| 7       | 57  | No        | 7,981,510              | DTG/ABC/3TC      | 1a       | Yes     | 12             | Yes                         |

3TC = lamivudine, ABC = abacavir, ART = antiretroviral treatment, ATV = ritonavir-boosted atazanavir, DTG = dolutegravir, EFV = efavirenz, FTC = emtricitabine, HCV VL = hepatitis C virus viral load, HIV VL = human immunodeficiency virus viral load, LDV/SOF = ledipasvir-sofosbuvir, RAL = raltegravir, RPV = rilpivirine, TDF = tenofovir disoproxil fumarate, tx = treatment.

Length of therapy noninferiority analysis have previously established 8 week regimens noninferior to 12 week regimens among HCV mono-infected persons. In our study, the SVR rate was 67% in the 8 weeks arm as compared to 96% in the 12-week arm. However, there were only 2 relapses in the 8-week arm and 1 of those patients had a baseline VL of 12,815,000 copies/mL, which is higher than the recommended cutoff for short course treatment with LDV/SOF. However, the number of patients receiving 8 week treatments were small and number of patients who had relapse were not sufficient to determine appropriate baseline response variables. Thirty-two percent of patients with cirrhosis underwent 24 weeks of LDV/SOF treatment, the remaining completed 12 weeks of treatment. The 1 patient with cirrhosis who relapsed had completed 24 weeks of therapy.

Since adherence could not be measured in real time, adherence was ascertained through documentation in provider notes and also the failure of concomitant ART with an increase in HIV VL. Only 1 of the 7 patients who relapsed had documented nonadherence to LDV/SOF; adherence data was not available for 6/7. Five patients (5%) had HIV VL breakthrough during treatment with LDV/SOF. Of these, 1 patient self-discontinued ART during treatment with HCV, 2 patients had documented intermittent nonadherence to ART. Two of the 5 patients with HIV VL breakthrough had HCV relapse, 3/5 achieved and sustained HCV suppression throughout the study period. Subgroup analysis of ART regimens in this study indicates a lower SVR rate for patients who were concomitantly taking efavirenz. In our study, there was only 1 participant on an efavirenz-based regimen who experienced a treatment relapse. Given only 5 patients were on efavirenz-based regimens, the 80% SVR rate cannot be considered robust and has high variability (confidence interval 28%, 95%, Fisher exact P = .317). Prior studies have suggested that the CYP2B6 polymorphism, more common in Black persons, is associated with higher serum efavirenz levels, though this was not found to be associated with relapse.[15] Fifty-eight percent of patients who had efavirenz in their ART regimen were switched to a different regimen by providers before initiating treatment with LDV/SOF.

Limitations of this study include retrospective data collection and provider dependent decisions. Given the retrospective nature of the study, there may be confounding factors that are unaccounted for. Further, genotype data for those who relapsed was not collected, therefore not definitively excluding the possibility of new infections vs true relapse. While this study achieves the purpose of measuring real-world success of LDV/SOF in a historically difficult-to-treat Black, HIV/HCV coinfect ed patient population, it also lends insight into provider variability in determining ultimate HCV treatment. Further, we did not capture impact of insurance restrictions as a factor on duration of therapy for this cohort of patients. Therefore, further studies are warranted to develop appropriate ART regimens and length of LDV/SOF therapy required for coinfected patients with and without cirrhosis.

Since the completion of this study, other DAs and pan-genotypic regimens such as glecaprevir/pibrentasvir, sofosbuvir/daclatasvir, and sofosbuvir/velpatasvir have been introduced with reported high SVR rates in chronic HCV treatment.[16–18] However, significant reported drug–drug interactions and restrictions of use in cirrhosis ultimately leads to continued provider variability in regimen choice.[17,18,20] This study demonstrates high SVR rate and efficacy of LDV/SOF in Black, HIV/HCV coinfected patients, though further studies are warranted to determine optimal regimens and durations of therapies while balancing patient characteristics, baseline data, and potential interactions with ART.

5. Conclusion
In conclusion, we found that in this real-world cohort of Black, HIV/HCV coinfected patients, LDV/SOF had a high SVR rate of 93%. This data supports the high overall efficacy of LDV/SOF even in historically difficult to treat populations.

Author contributions
Conceptualization: Shobha Swaminathan.
Data curation: Jaspreet Banga, Sobia Nizami, Jihad Slim, Sandhya Nagarakanti, Mario Portilla, Shobha Swaminathan.
Formal analysis: Jaspreet Banga, Sobia Nizami, Jihad Slim, Sandhya Nagarakanti, Shobha Swaminathan.
Funding acquisition: Shobha Swaminathan.
Investigation: Jaspreet Banga, Jihad Slim, Sandhya Nagarakanti, Shobha Swaminathan.
Supervision: Shobha Swaminathan.
Writing – original draft: Jaspreet Banga.
Writing – review & editing: Jaspreet Banga, Sobia Nizami, Jihad Slim, Sandhya Nagarakanti, Shobha Swaminathan.

References
[1] Denniston AU, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293.
[2] HIV and Viral Hepatitis Fact Sheet 2017. Centers for Disease Control and Prevention. June 2017. Available at: https://www.cdc.gov/hiv/pdf/library/factsheets/hiv-viral-hepatitis.pdf. Accessed January 19, 2019.
Rosenthal ES, Kottilil S, Polis MA. Sofosbuvir and ledipasvir for HIV/HCV co-infected patients. Expert Opin Pharmacother 2016;17:743–9.

Lo Re V, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014;160:369–79.

Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418–31.

de Ledinghen V, Barreiro P, Foucher J, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat 2008;15:427–33.

Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis 2013;56:1038–43.

Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013;158:658–66.

Afshal N, Zeuzem S, Kwo P, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–98.

Afshal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–93.

Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–88.

Naggie S, Cooper C, Saag M, et al. ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705–13.

Backus LL, Belperio PS, Shahouman TA, et al. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology 2016;64:405–14.

Isakov V, Gankina N, Morozov V, et al. Ledipasvir-sofosbuvir for 8 weeks in non-cirrhotic patients with previously untreated genotype 1 HCV infection ± HIV-1 co-infection. Clin Drug Investig 2018;38:239–47.

Haas DW, Ribaudo HJ, Kim RR, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004;18:2391–400.

Rockstroh JK, Lacombre K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDIATION-2 study. Clin Infect Dis 2018;67:1010–7.

Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol 2019;15(5 Supp 3):1–2.

Liu CH, Liu CJ, Hung CC, et al. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: real-world effectiveness and safety in Taiwan. Liver Int 2019.

Kosloski MP, Oberoi R, Wang S, et al. Drug-drug interactions of glecaprevir and pibrentasvir coadministered with human immunodeficiency virus antiretrovirals. J Infect Dis 2020;221:223–31.

Lampejo T, Agarwal K, Carey I. Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: a literature review. Dig Liver Dis 2018;50:113–23.